Dexcel Pharma Technologies Ltd.

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Activity

Key Events

Jul 18, 2023FDAPrilosec — PRILOSEC

Jul 18, 2023FDANexium — NEXIUM

Sep 6, 2022FDANexium — NEXIUM 24HR

Mar 4, 2022FDANexium — NEXIUM

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

5 patent groups across drugs · Source: FDA Orange Book

DrugExpires

PeridexApr 25, 2026 PeridexOct 2, 2027 PrilosecJan 31, 2030 NexiumDec 8, 2036 PrilosecDec 8, 2036

Regulatory

Regulatory Timeline

20191 event

FDAApr 4

Nexium — NEXIUM 24HR

Application NDA207920

20206 events

FDADec 4

Nexium — NEXIUM 24HR

Application NDA204655

FDANov 27

Nexium — NEXIUM

Application NDA021153

FDANov 27

Nexium — NEXIUM

Application NDA022101

FDANov 27

Nexium — NEXIUM

Application NDA021957

FDANov 27

Prilosec — PRILOSEC

Application NDA022056

FDAOct 20

Nexium — ESOMEPRAZOLE MAGNESIUM

Application NDA214278 (NDA)

20213 events

FDAAug 25

Nexium — NEXIUM

Application NDA022101

FDAAug 25

Nexium — NEXIUM

Application NDA021957

FDAAug 25

Nexium — NEXIUM

Application NDA021153

20226 events

FDASep 6

Nexium — NEXIUM 24HR

Application NDA207920

FDASep 6

Nexium — NEXIUM 24HR

Application NDA204655

FDAMar 4

Nexium — NEXIUM

Application NDA021153

FDAMar 4

Nexium — NEXIUM

Application NDA022101

FDAMar 4

Prilosec — PRILOSEC

Application NDA022056

FDAMar 4

Nexium — NEXIUM

Application NDA021957

20234 events

FDAJul 18

Prilosec — PRILOSEC

Application NDA022056

FDAJul 18

Nexium — NEXIUM

Application NDA021153

FDAJul 18

Nexium — NEXIUM

Application NDA021957

FDAJul 18

Nexium — NEXIUM

Application NDA022101

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)